Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Bibliographic record

Risk of gastrointestinal adverse events associated with glucagon-like peptide-1 receptor agonists for weight…

Sodhi M, Rezaeianzadeh R, Kezouh A, Etminan M. JAMA 2023

Document identifier
CEI-BR-102
Series
Bibliographic record
Version
1.0
Published
30 Jul 2026
Last reviewed
30 Jul 2026
Certainty
Not rated

§1Bibliographic record

§1.1Record

Authors
Sodhi M, Rezaeianzadeh R, Kezouh A, Etminan M
Title
Risk of gastrointestinal adverse events associated with glucagon-like peptide-1 receptor agonists for weight loss
Source
JAMA
Year
2023
Volume, issue, pages
330(18):1795–1797
Digital object identifier
10.1001/jama.2023.19574
PubMed identifier
37796527
Record type
Journal article
Institute identifier
CEI-BR-102

§1.2Institute documents citing this record

Table 1. Documents in the Institute set that cite this record.

§1.3Subject tags

glp-1 safety pharmacoepidemiology

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.